Hengrui Pharmaceutical (600276.SH): HRS-8797 tablets obtained drug clinical trial approval notice

Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Chengdu Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for HRS-8797 tablets, which will conduct clinical trials in the near future.

HRS-8797 tablets are a class 1 innovative drug for the treatment of atopic dermatitis independently developed by the company. After inquiry, no similar drug has been approved for marketing worldwide. Up to now, the total R&D investment for HRS-8797 film-related projects is approximately RMB 32.9 million (unaudited).